Detalhe da pesquisa
1.
Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate.
Vaccine;
37(30): 3957-3960, 2019 07 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31155419
2.
LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs.
Clin Exp Metastasis;
34(3-4): 241-249, 2017 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28417212
3.
Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen.
Springerplus;
2(1): 12, 2013 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23483788
4.
A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
Vaccine;
29(5): 920-30, 2011 Jan 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21145912
5.
Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.
ISRN Obstet Gynecol;
2011: 292951, 2011.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21748025
6.
Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors.
Vaccine;
23(50): 5768-74, 2005 Dec 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16112257